IRVINE, Calif.--(BUSINESS WIRE)--Sep. 30, 2016--
Masimo (NASDAQ:
MASI) announced today that it is partnering with Smile Train to help
ensure the safety of patients undergoing cleft lip and/or palate surgery
in low-resource settings around the world.
Patient monitoring, including the use of pulse oximetry, is a key part
of ensuring safe surgical care; however, in lower-resource settings
essential monitoring equipment is often unavailable, particularly in the
post-operative period.1 Working together, Smile Train and
Masimo are helping to remove this barrier by equipping surgical programs
in 15 countries in Asia, Africa, Central America, and the Middle East
with pulse oximeters.
Smile Train is an international organization that leverages the “teach a
man to fish” model to train and empower local medical professionals to
provide safe, high-quality, comprehensive cleft treatment for children
in their own communities. Through Smile Train’s local partnerships in
85+ countries, the organization has provided more than 1,000,000 cleft
surgeries to date.
Through this partnership, Masimo is providing over 460 Masimo SET®
Measure-through Motion and Low Perfusion™ pulse oximeters to Smile
Train’s nurse training programs and partner hospitals to support
improved patient monitoring and safety. Additionally, Masimo and Smile
Train will work together to develop additional initiatives to ensure
that post-operative pulse oximetry can be scaled across all Smile Train
programs.
One of the most common birth defects in the world, a cleft lip and/or
palate occurs before a child is born, when the lip and/or roof of the
mouth fail to fuse together properly during fetal development. In
higher-resource settings virtually all babies with clefts have
reconstructive surgery as it is relatively simple, inexpensive, and
immediately transformative. This is not the case in lower-resource
settings, where, as highlighted by the World Federation of Societies of
Anaesthesiologists’ SAFE-T Campaign, an estimated 70% of the world’s
population do not have access to safe and affordable anesthesia and
surgical care.1,2 This startling gap in surgical access means
the estimated 170,000 children born with clefts in lower-resource
settings do not receive surgical treatment and live with difficulties
eating, breathing, speaking, and, in the longer term, are less likely to
enroll in school or hold jobs due to the stigmas associated with
physical defects.3
“Proper surgical monitoring, including essential pulse oximetry, is
crucially important to ensuring safe surgical outcomes. Smile Train is
excited to partner with Masimo to make their high-performing, Signal
Extraction Technology pulse oximeters available at Smile Train partner
hospitals as we work together to continue providing safe and quality
cleft care to children in need all over the world,” said Susannah
Schaefer, CEO of Smile Train.
“One of the greatest joys is seeing a smile on the face of a child.
Every child on earth deserves to have access to safe surgery, to be
treated with dignity and love, and to share their beautiful smiles,”
said Joe Kiani, Founder and CEO of Masimo. “Partnering with Smile Train
is a fundamental part of our commitment to the Sustainable Development
Goals and to our belief that no matter where a person lives or where
they were born, access to quality healthcare that is dignified and safe
is a human right, not a privilege. We are very proud of the work that
Smile Train has done to improve surgical safety and access for cleft
patients in local communities around the world. We value their
commitment to scaling the use of quality pulse oximetry to all programs.”
Friday, October 7th is World Smile Day®, on which
we are reminded to “Do one act of kindness. Help a person smile!”4
The smile is an international symbol of peace, happiness, and kindness
that knows no barriers or boundaries. Masimo and Smile Train are proud
to be partnering to bring smiles to the faces of children around the
globe, not just on World Smile Day®, but on every day of the
year. We encourage everyone to participate in World Smile Day®
this year!
@MasimoInnovates |
#Masimo
References
-
Meara JG et al. Global Surgery 2030: evidence and solutions for
achieving health, welfare, and economic development. Lancet.
2015 Aug 8;386(9993):569-624
-
World Federation of Anaesthesiologists (WFSA) Safe Anaesthesia For
Everybody – Today “SAFE-T” Campaign, 2016. http://www.wfsahq.org/get-involved/safe-t.
-
Smile Train Medical Advisory Board.
-
http://www.worldsmileday.com/.
About Masimo
Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive
monitoring technologies. Our mission is to improve patient outcomes and
reduce the cost of care by taking noninvasive monitoring to new sites
and applications. In 1995, the company debuted Masimo SET®
Measure-through Motion and Low Perfusion™ pulse oximetry, which has been
shown in multiple studies to significantly reduce false alarms and
accurately monitor for true alarms. Masimo SET® is estimated
to be used on more than 100 million patients in leading hospitals and
other healthcare settings around the world. In 2005, Masimo introduced
rainbow® Pulse CO-Oximetry technology, allowing noninvasive
and continuous monitoring of blood constituents that previously could
only be measured invasively, including total hemoglobin (SpHb®),
oxygen content (SpOC™), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), and more recently, Pleth Variability
Index (PVI®) and Oxygen Reserve Index (ORi™), in addition to
SpO2, pulse rate, and perfusion index (PI). In 2014, Masimo
introduced Root®, an intuitive patient monitoring and
connectivity platform with the Masimo Open Connect™ (MOC-9™) interface.
Masimo is also taking an active leadership role in mHealth with products
such as the Radius-7™ wearable patient monitor and the MightySat™
fingertip pulse oximeter. Additional information about Masimo and its
products may be found at www.masimo.com.
All published clinical studies on Masimo products can be found at http://www.masimo.com/cpub/clinical-evidence.htm.
About Smile Train
Smile Train is an international children’s charity with a sustainable
approach to a single, solvable problem: cleft lip and palate. Millions
of children in developing countries with untreated clefts live in
isolation, but more importantly, have difficulty eating, breathing and
speaking. Cleft repair surgery is simple, and the transformation is
immediate. Our sustainable model provides training, funding, and
resources to empower local doctors in 85+ developing countries to
provide 100%-free cleft repair surgery and comprehensive cleft care in
their own communities. To learn more, please visit smiletrain.org.
Forward-Looking Statements
This press release includes forward-looking statements as defined in
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, in connection with the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements include, among others, statements regarding the potential
effectiveness of Masimo pulse oximetry. These forward-looking statements
are based on current expectations about future events affecting us and
are subject to risks and uncertainties, all of which are difficult to
predict and many of which are beyond our control and could cause our
actual results to differ materially and adversely from those expressed
in our forward-looking statements as a result of various risk factors,
including, but not limited to: risks related to our assumptions
regarding the repeatability of clinical results; risks related to our
belief that Masimo's unique noninvasive measurement technologies,
including Masimo pulse oximetry, contribute to positive clinical
outcomes and patient safety; risks related to our belief that Masimo
noninvasive medical breakthroughs provide cost-effective solutions and
unique advantages; as well as other factors discussed in the "Risk
Factors" section of our most recent reports filed with the Securities
and Exchange Commission ("SEC"), which may be obtained for free at the
SEC's website at www.sec.gov.
Although we believe that the expectations reflected in our
forward-looking statements are reasonable, we do not know whether our
expectations will prove correct. All forward-looking statements included
in this press release are expressly qualified in their entirety by the
foregoing cautionary statements. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of
today's date. We do not undertake any obligation to update, amend or
clarify these statements or the "Risk Factors" contained in our most
recent reports filed with the SEC, whether as a result of new
information, future events or otherwise, except as may be required under
the applicable securities laws.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160930005929/en/
Source: Masimo
Masimo
Evan Lamb, 949-396-3376
elamb@masimo.com
or
Smile
Train
Shari Mason, 212-689-9199
smason@smiletrain.org